Huadong Medicine (000963.SZ) Subsidiary's HDM4002 Injection Clinical Trial Application Approved

Stock News11-18 17:02

Huadong Medicine Co., Ltd. (000963.SZ) has announced that on November 17, 2026, its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Zhongmei Huadong") received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting approval for the clinical trial application of HDM4002 Injection filed by Zhongmei Huadong. This drug is intended for the treatment of adult patients with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression, in order to reduce the loss of kidney function. This approval represents an important milestone in the product's research and development process and will further enhance the company's core competitiveness in the field of autoimmune therapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment